• Kontakt
• So finden Sie uns
• Klinikumseinrichtungen
• Presse

Ausgewählte Publikationen

• Elsässer-Beile, U., Gutzeit, O., Bauer, S., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U.: Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. J. Urology, 163, 296-299, 2000zweitens
•  Elsässer-Beile, U., Przytulski, B., Gierschner, D., Grussenmeyer, T., Katzenwadel, A., Leiber, C., Deckart, A., Wetterauer, U.: Comparison of the activation status of infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. The Prostate, 45, 1-7, 2000
•  Elsässer-Beile, U., Rindsfüser, M., Grussenmeyer, T., Schultze-Seemann, W., Wetterauer, U.: Enhanced expression of IFN-( mRNA in CD4+, and CD8+ tumor infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell carcinomas. Brit. J. Cancer, 83, 637-642, 2000
•  Elsässer-Beile, U., Voss, M., Schühle, R., Wetterauer, U.: Biological effects of natural and recombinant Mistletoe lectin and an aqueous Mistletoe extract on human monocytes and lymphocytes in vitro. J. Clin. Lab. Anal.14, 255-259, 2000
•  Elsässer-Beile, U. Schultze-Seemann, W, Wetterauer, U.: “Das Prostatakarzinom” in “Handbuch der Molekularen Medizin, Band 10. Springer-Verlag, 2001
•  Elsässer-Beile, U., Ruhnau, T., Freudenberg, N., Wetterauer, U., Mengs, U.: Antitumoral effect of recombinant Mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer, 91, 1005-1012, 2001
•  Elsässer-Beile, U. Gierschner, D., Welchner, T., Wetterauer, U. Different Expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas. Anticancer Res. 23, 433-438, 2003
•  Elsässer-Beile U., Gierschner D., Jantscheff P., Schultze-Seemann W., Katzenwadel A., Wetterauer, U. Different basal expression of type T1 and T2 cytokines in peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Anticancer Res. 23, 4027- 4032, 2003
•  Elsässer-Beile, U., Leiber, Ch., Wetterauer U., Mengs, U.: Adjuvant instillation therapy of superficial urothelial bladder carcinoma with a standardized mistletoe extract. J. Cancer Res. and Clinical Oncology Suppl. Jan 2004
•  U. Elsässer-Beile, C. Leiber, P. Wolf, M. Lucht, U. Mengs and U. Wetterauer: Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J. Urol 174, 76-79, 2005
•  Elsässer-Beile, U., Wolf, Ph. Gierschner, D., Bühler, P., Wetterauer, U.Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen as diagnostic and therapeutic tools for prostate cancer. European Patent Application No. 05011536.9 (27.5.2005)
•  Elsässer-Beile, U., Leiber, C., Wetterauer, U., Bühler, P., Wolf, Ph., Lucht, M., Mengs, U.: Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. Anticancer Res. 25, 4733-4736, 2005
•  Elsässer-Beile, U., Wolf, P., Gierschner, D., Bühler, P., Schultze-Seemann, W., and Wetterauer, U.. A New Generation of Monoclonal and Recombinant Antibodies against Cell-Adherent Prostate Specific Membrane Antigen for Diagnostic and Therapeutic Targeting of Prostate Cancer. The Prostate in press 2006
•  Wolf, P., Gierschner, D., Bühler, P., Wetterauer, U., Elsässer-Beile, U.: A Fully Recombinant PSMA-specific Single-Chain Immunotoxin (A5-PE40) has Potent and Selective Toxicity Against Prostate Cancer Cells. Cancer Immunology, Immunotherapy, online 03 2006
•  Elsässer-Beile,U.,Leiber, C.,Bühler,P.,Mengs,U.,Wetterauer,U.;Adjuvant intravesical treatment of superficial urinary bladder cancer with Mistletoe extract. Tumor Biol, Vol 27 Suppl 1, p 25 2006
•  Bühler, P., Elsässer, U., Freudenberg, N., Wetterauer, U. Primary Tumor Cultures as Model for Androgen Depletion of Prostate cancer. Tumor Biol Vol 27 Suppl 1 P 56 2006